Ann: Smoking cessation trial results of ongoing data analysis, page-31

First 31 Last

Share
Profile

Follow
nequalsone

341 Posts.

911

26/11/15

07:00

Post #: 16479871
Share

Originally posted by matakus ↑

Lets just start by saying that this is where the market perception of Invion's worth is one cause for the pathetic sp we are now seeing.
Extract from Delaware Online re oral Nadalol for smoking cessation:
"Nadolol is potentially harmful for people with lung disease, a contra-indication Invion hopes to challenge by developing a gradual increase in dosage that can be patented and sold in the next two years at a total market value between $500 million and $1 billion in the United States alone."

Inhaled version,keeping in mind this is the only drug that will heal the lungs by blocking mucus production which is the major cause of death in asthma ,copd and cystic fibrosis and can also be combined with other lung medications.So this will be first in class in a $50B plus market.

"A year earlier, AstraZeneca acquired Pearl Therapeutics for up to $1.15 billion after the private, California-based company raised $232 million over six years to take a repurposed generic to late-stage trial for the treatment of COPD.
Chris Yochim, a former head of external relations for AstraZeneca and the current chairman of the Delaware BioScience Association, said Invion is well positioned to follow suit." --( And this was only after completing Phase II)
So lets say ours maybe be worth north of $1.15 B

"Repurposing drugs, from big pharma's perspective, is a concept whose time has come, and they look to extract value from all their products – including those that might have been shelved in years past – by working with small, nimble companies that are able to develop new ways to apply those assests," he said. "Mitchell is one of the unsung superheroes and there is real potential that Invion will see huge demand for its drugs once they reach proof of concept." ( Proof of concept has been achieved.)

Re Zafirlukast:
"Turning it into an inhalable has proven to be a difficult nut to crack, but we've partnered with a company – which we'll announce very soon – that has formulated it into a dry powder inhaler," he said. "We've already had two companies take a good look at it, and they say sales figures will start with a b."

Cpn10 ia an unknown value!

So are we really only worth between$20-$80 million.I'm sure Mitchell would not get out of bed or retirement for for this amount.

Had a chat to Bill Garner after agm and added that if listed on the Nasdaq we would currently be looking at dollars per share.
It is no wonder Australian Biotech companies eventually go os.No support here!

Expand

Thanks for sharing your research matakus. It's greatly appreciated.
I'm hoping the spp will be strongly supported and we can get a highly lucrative partnership deal signed off on without the need to go chasing capital elsewhere.

IVX Price at posting: 0.8¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 3 more messages in this thread...

First 31 Last

Add IVX (ASX) to my watchlist

(20min delay)
Last 0.3¢		Change 0.001(50.0%)		Mkt cap ! $20.29M

Open	High	Low	Value	Volume
0.3¢	0.3¢	0.3¢	$31.75K	10.58M

Buyers (Bids)

No.	Vol.	Price($)
8	8744053	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.4¢	6699589	13

View Market Depth

No.	Vol.	Price($)
8	8744053	0.003
61	52410291	0.002
22	28267144	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.004	6699589	13
0.005	7799568	25
0.006	1883326	6
0.007	1262000	3
0.008	3905000	4

Last trade - 10.19am 27/09/2024 (20 minute delay)

IVX (ASX) Chart

Ann: Smoking cessation trial results of ongoing data analysis, page-31

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Zeta Resources seeks to resolve the Panoramic takeover story

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Smoking cessation trial results of ongoing data analysis, page-31

Top Stories

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Zeta Resources seeks to resolve the Panoramic takeover story

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News